Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.43B | 4.44B | 4.42B | 4.42B | 4.76B | 3.27B |
Gross Profit | 2.04B | 1.91B | 1.94B | 2.50B | 2.63B | 1.61B |
EBITDA | 626.00M | 1.49B | -224.00M | 866.00M | 409.00M | -76.80M |
Net Income | 373.00M | 338.00M | -1.23B | -74.00M | -472.00M | -560.10M |
Balance Sheet | ||||||
Total Assets | 12.94B | 12.61B | 14.36B | 15.49B | 16.48B | 17.69B |
Cash, Cash Equivalents and Short-Term Investments | 487.00M | 468.00M | 352.00M | 345.00M | 638.00M | 494.70M |
Total Debt | 4.39B | 4.32B | 5.77B | 5.84B | 6.32B | 6.13B |
Total Liabilities | 6.59B | 6.52B | 8.14B | 8.20B | 8.95B | 9.22B |
Stockholders Equity | 6.35B | 6.10B | 6.22B | 7.29B | 7.54B | 8.48B |
Cash Flow | ||||||
Free Cash Flow | 341.00M | 394.00M | 117.00M | 268.00M | 286.00M | -351.90M |
Operating Cash Flow | 535.00M | 541.00M | 271.00M | 452.00M | 483.00M | -41.00M |
Investing Cash Flow | 1.06B | 1.16B | -169.00M | -179.00M | -530.00M | -4.78B |
Financing Cash Flow | -1.41B | -1.49B | -83.00M | -549.00M | 210.00M | 4.95B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $7.19B | 19.31 | 6.01% | ― | 1.42% | ― | |
62 Neutral | $9.09B | 23.21 | 11.78% | ― | 1.75% | 8.76% | |
61 Neutral | $2.64B | ― | 106.97% | ― | 13.42% | 92.50% | |
55 Neutral | $2.19B | 48.01 | -16.56% | ― | 53.40% | -230.86% | |
55 Neutral | $3.74B | ― | -3.64% | 4.26% | -4.85% | -4290.31% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% | |
45 Neutral | $1.16B | ― | -16.71% | ― | -2.50% | -30760.27% |
On June 25, 2025, Elanco Animal Health Incorporated, along with Elanco SPEAR LLC and Elanco US Inc., amended its Receivables Loan Agreement with Rabobank, extending the term of the agreement to June 26, 2028. This amendment impacts the company’s accounts receivable securitization facility, potentially affecting its financial obligations and operational flexibility.
The most recent analyst rating on (ELAN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.
On May 28, 2025, Elanco Animal Health announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen, who previously held leadership roles at Hillenbrand, Inc. and Johnson Controls, will succeed Todd Young, who will remain as an advisor until August 31, 2025, to ensure a smooth transition. This strategic appointment is part of Elanco’s commitment to long-term value creation, with VanHimbergen’s extensive experience expected to support the company’s growth and innovation initiatives. The transition marks a proactive change as Elanco continues to focus on accelerating growth, expanding margins, and enhancing shareholder value.
The most recent analyst rating on (ELAN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.
On May 16, 2025, Elanco Animal Health held its annual meeting of shareholders where all board-nominated directors were elected for a one-year term. Shareholders ratified Ernst & Young LLP as the independent accounting firm for 2025, approved executive compensation, and decided on an annual advisory vote on executive compensation until 2031, aligning with the board’s recommendation.
The most recent analyst rating on (ELAN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.